Log in to search using one of your social media accounts:

 

Head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic CRPC
The approval of enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) provided an important life-extending drug. Now the sequencing and uses of enzalutamide are bei... Author: VJOncology Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Differentiating aggressive vs. non-aggressive prostate cancer: the MiCheck GPC1 biomarker test
The addition of a new prostate cancer diagnostic test to inform clinicians and patients prior to the decision to biopsy would be beneficial, in conjunction with the traditional measures of PSA and DRE... Author: VJOncology Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

How will new NSAAs impact clinical practice in prostate cancer?
Previously, patients with nonmetastatic castration-resistant prostate cancer (nmCRPRC) and the clinicians treating them had no therapeutic options to delay disease progression. Now there are two new n... Author: VJOncology Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Live long and PROSPER: enzalutamide for nmCRPC
There has previously been no approved treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC), due to a lack of evidence that any drug would prevent disease progression in this popul... Author: VJOncology Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Supporting young hematology researchers: training programs offered by EHA and ASH
This interview provides an exciting insight into the Translational Research Training in Hematology (TRTH) and the Clinical Research Training in Hematology (CRTH) programs, offered to junior hematology... Author: VJHemOnc Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel methods to assess the effectiveness of chemotherapy in AML patients: MRD
It is extremely important to assess the long-term effects of chemotherapy in patients with acute myeloid leukemia (AML); however, with the knowledge of minimal residual disease, it is understood that ... Author: VJHemOnc Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD... Author: Genitourinary-Cancer-Meeting Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunothera... Author: Genitourinary-Cancer-Meeting Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses tUsing Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements at... Author: Genitourinary-Cancer-Meeting Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients at the 2018 ASCO. Author: Genitourinary-Cancer-Meeting Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Overlooked Biomarker May Predict Cancer Immunotherapy Response
Dr David Kerr on data showing that tumors with extensive aneuploidy may not benefit as much from immune checkpoint blockade. (Source: Medscape Oncology)
Source: Medscape Oncology - February 15, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Beyond APHINITY: What Now After Pivotal Breast Cancer Trial?
Dr Kathy Miller speaks with APHINITY's principal investigator about whether survival in HER2+ disease can be pushed even further. (Source: Medscape Oncology)
Source: Medscape Oncology - February 15, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

"We don't really know the impact of these products on our health": Ultraprocessed food & cancer risk
A study published by The BMJ today reports a possible association between intake of highly processed ( “ultra-processed”) food in the diet and cancer. Ultra-processed foods include packaged baked goods and snacks, fizzy drinks, sugary cereals, ready meals and reconstituted meat products - often containing high levels of sugar, fat, and salt, but... (Source: The BMJ Podcast)
Source: The BMJ Podcast - February 15, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts

Obesity's Impact on Screening for Cervical Cancer
Dr Andrew Kaunitz highlights an important study, with implications for vaginal examination and cervical cancer screening in obese women. (Source: Medscape ObGyn Podcast)
Source: Medscape ObGyn Podcast - February 14, 2018 Category: OBGYN Authors: Medscape Source Type: podcasts

MABp1: 'Clever' New Antibody Targeting Colorectal Cancer
A trial using MABp1, an antibody targeting interleukin 1 alpha, showed some benefit for patients with advanced colorectal cancer, but Dr Kerr thinks the clinical endpoint used was a'little soft.'(Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - February 14, 2018 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

Excluding PE in Low-Risk ED Patients, Screening for Ovarian Cancer, COIs in Nutrition Research, and more
Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the February 13, 2018 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - February 13, 2018 Category: General Medicine Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts

USPSTF Recommendation: Screening for Ovarian Cancer
Interview with Michael J. Barry, MD, Task Force member and co-author of Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - February 13, 2018 Category: General Medicine Authors: The JAMA Network Source Type: podcasts

Exciting randomized trials for mesothelioma: checkpoint inhibitor monotherapies and vinorelbine
Only one treatment for malignant mesothelioma has been approved since 2003 and rates of the disease are rising worldwide; thus, new treatments must be found. Here, Dean Fennell, PhD, FRCP, of Universi... Author: VJOncology Added: 02/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 13, 2018 Category: Cancer & Oncology Source Type: podcasts

Cutting-edge UK trials for mesothelioma: double immuno, arginine depletion and molecular profiling
There is currently an array of exciting clinical trials for mesothelioma, investigating cutting-edge treatments in large patient groups. Here, Dean Fennell, PhD, FRCP, of University Hospitals of Leice... Author: VJOncology Added: 02/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 13, 2018 Category: Cancer & Oncology Source Type: podcasts

Mesothelioma biology: key genes and therapeutic targeting
There has been a vast increase in our understanding of the pathology of mesothelioma in the past 5 years, which is hoped to revolutionize the treatment of the disease, whose incidence is rising global... Author: VJOncology Added: 02/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 13, 2018 Category: Cancer & Oncology Source Type: podcasts

Mesothelioma: the key unanswered question
Mesothelioma cases are on the rise, in both developed and developing countries. Thus, increased understanding of the underlying mechanisms of the disease is essential. Here, Dean Fennell, PhD, FRCP, o... Author: VJOncology Added: 02/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 13, 2018 Category: Cancer & Oncology Source Type: podcasts

An MRI-based approach to prostate cancer diagnosis: a urologists stance in the debate
The first study illustrating the potential of MRI in the diagnosis of prostate cancer was published in 2006. Although there have since been a number of other studies showing this utility, the use of M... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

Challenges for prostate cancer: overdiagnosis and unnecessary treatment
The current diagnostic methods for prostate cancer are not always as reliable or accurate as they could be, leading to mis- or over-diagnosis, and thus the treatment of patients who will not benefit f... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

Is delayed diagnosis in the UK to blame for poorer cancer outcomes?
Recent news reports have identified poorer outcomes in cancer patients from the UK compared with those in certain other European countries. Here, Mark Emberton, MD, FRCS, of University College London,... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

MRI-based prostate cancer diagnosis: economic and logistical considerations
The take-home message from the 2018 Genitourinary Cancers Symposium, in San Francisco, CA, on MRI for prostate cancer diagnosis was positive. However, this leaves us with a variety of questions. In th... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

MRI and MRI-directed biopsies for the diagnosis of prostate cancer
The utilization of MRI for the diagnosis of prostate cancer in men at risk is relatively new. In this interview, filmed at the 2018 Genitourinary Cancers Symposium, in San Francisco, CA, Mark Emberton... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

Teamwork between urologists and oncologists in the UK
Current practice in the UK requires urologists to refer patients with urological cancer to oncologists for treatment. In this interview, Mark Emberton, MD, FRCS, of University College London, London, ... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

This is SPARTAN! Apalutamide treatment for nmCRPC
Highly anticipated data from the Phase III SPARTAN study (NCT01946204), which investigated apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC), was presented at the 2018 Genito... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

Straightforward study design: SPARTAN trial of apalutamide for nmCRPC
There has previously been no effective treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC). Now there are several exciting late-phase clinical trials investigating promising trea... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

SPARTAN vs. PROSPER: apalutamide or enzalutamide for nmCRPC?
With exciting data from the Phase III SPARTAN (NCT01946204) and PROSPER (NCT02003924) trials of apalutamide and enzalutamide, respectively, for the treatment of nonmetastatic castration-resistant pros... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

How will the results of the SPARTAN study impact US clinical practice in prostate cancer?
The emergence of an effective treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is likely to have a paradigm-changing effect on the treatment of CRPC. In this informative talk ... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

Nonmetastatic CRPC: meeting an unmet need
Nonmetastatic castration-resistant prostate cancer (nmCRPC) is a disease which had no FDA-approved treatment. Following the completion of the Phase III SPARTAN trial (NCT01946204), a new nonsteroidal ... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

How do we select the urothelial carcinoma patients who will benefit from checkpoint inhibitors?
With the emergence of five novel immune checkpoint inhibitors for the treatment of urothelial carcinoma, the key question now arising is how to identify the subgroups of patients who will benefit from... Author: VJOncology Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

PD-L1 and TMB as biomarkers in the IMvigor211 trial of atezolizumab vs. chemo for bladder cancer
A highly anticipated topic at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, was immune checkpoint inhibitor data for bladder cancer. Here, Thomas Powles, MD, of Barts Cancer Ins... Author: VJOncology Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Will immune checkpoint inhibitors become the new standard of care for urothelial cancer?
Immune checkpoint inhibitors for urothelial carcinoma in the relapsed/refractory setting have already been approved and are superseding standard chemotherapy. Now, there are exciting late-phase clinic... Author: VJOncology Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Immune checkpoint inhibitors for urothelial carcinoma: the current landscape
Novel immune checkpoint inhibitors that are entering the clinic are changing the way in which we treat metastatic urothelial carcinoma, the most common type of bladder cancer. In this interview, Thoma... Author: VJOncology Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

MRD studies in ALL and AML
Minimal residual disease (MRD) monitoring is a promising and controversial topic, with its increasing use in clinical trials being followed acutely. Speaking from the American Society of Hematology (A... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Current management of Ph-positive ALL
There was exciting new trial data for the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposi... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Decitabine dosing regimens in older AML patients: 5-day vs. 10-day, is there a difference?
Older acute myeloid leukemia (AML) patients are not typically given intensive cytotoxic chemotherapy due to their fragility and comorbidities. Decitabine has previously been demonstrated to improve su... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Ruxolitinib plus decitabine in post-MPN AML
The outcomes of patients with post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML) are poor, with no standard therapy. In this interview, Farhad Ravandi, MD, from the University of T... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Triple therapy including nivolumab for newly diagnosed AML
Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the pilot Phase II study (NCT02464657) of cytarabine, idarubicin and the PD-1 inhibitor... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Multiple myeloma highlights at ASH 2017
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, was an exciting one for multiple myeloma (MM) data. In this interesting interview, Graham Jackson, FRCP, FRC... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Selective Internal Radiotherapy Fails Again in mCRC
Dr David Kerr on the latest setback from this once promising therapy. (Source: Medscape Oncology)
Source: Medscape Oncology - February 9, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Myeloma XI trial: impact of MRD on treatment response in MM
Minimal residual disease (MRD) is the major cause of relapse in multiple myeloma (MM), and measurements of its level can be utilized to determine treatment response and prognosis. Here, Graham Jackson... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Myeloma XI trial: lenalidomide maintenance therapy for multiple myeloma
At the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Graham Jackson, FRCP, FRCPath, MD, of Newcastle University, Newcastle, UK, was selected to present data f... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

IDEA Trial Remakes Adjuvant Chemo in Colorectal Cancer
Dr David Kerr on how one of the biggest studies at ASCO is already changing practice. (Source: Medscape Oncology)
Source: Medscape Oncology - February 9, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Copanlisib for relapsed/refractory NHL: results of the CHRONOS-1 study
Copanlisib is a novel PI3K inhibitor, targeting both PI3K- and PI3K- isoforms in malignant B-cells. It was granted FDA approval based on data from the Phase II CHRONOS-1 study (NCT01660451) investig... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Ibrutinib combination therapy in CLL: overview of the data so far
Ibrutinib combination therapy in an exciting therapeutic area with great potential. Many recent and ongoing studies are seeking to identify the optimal ibrutinib combinations for the treatment of chro... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

MURANO study: exciting times in CLL
Data from the Phase III MURANO study (NCT02005471) in relapsed/refractory chronic lymphocytic leukemia (CLL) was highly anticipated at the American Society of Hematology (ASH) 2017 Annual Meeting and ... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

PEP-C for lymphoma palliative care: a regional experience in the UK
Treating lymphoma patients in the relapsed/refractory setting often proves a challenge for physicians. PEP-C (prednisolone, etoposide, procarbazine and cyclophosphamide) is a chemotherapy regimen used... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts